Interim data from a Phase 3 trial failed to show that a combination of nemvaleukin, an experimental immune-modulating therapy, and Keytruda (pembrolizumab) could outperform standard…
Gynecological cancer
Treatment with AbbVie’s Elahere (mirvetuximab soravtansine) reduced the risk of death by 32% in women with difficult-to-treat epithelial ovarian cancer over standard chemotherapy. That’s according…
A Phase 1 clinical trial testing Nikang Therapeutics’ oral therapy NKT3964 in people with certain advanced or metastatic solid tumors, including gynecological cancers,…
In a rare case, a woman in China was found to have fallopian tube cancer in her left tube that had spread to lymph nodes…
Allarity Therapeutics will soon start recruiting patients at several U.S. sites for a new dosing protocol in its Phase 2 trial testing stenoparib…
The U.S. Food and Drug Administration (FDA) has granted fast-track status to CUSP06, Oncusp Therapeutics’ treatment candidate for platinum-resistant ovarian cancer. This designation…
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Gradalis’ experimental immunotherapy platform Vigil (Gemogenovatucel-T) as…
About a third of women with cyclin E1+ platinum-resistant ovarian cancer (PROC) responded to treatment with azenosertib, an experimental therapy by Zentalis. That’s according…
Sempervirine, a compound isolated from a plant used in traditional Chinese medicine, inhibited the growth, spread, and development of ovarian cancer cells in cell…
Discrepancies were identified between two genetic analysis platforms used to detect mutations that guide the treatment of ovarian, fallopian tube, or primary peritoneal cancers in…
